

Local and Systemic Immune Responses to Rectal Administration of Recombinant Cholera Toxin B Subunit in Humans

MARIANNE JERTBORN,^{1,2*} INGER NORDSTRÖM,¹ ANDERS KILANDER,³
CECIL CZERKINSKY,^{1†} AND JAN HOLMGREN¹

*Department of Medical Microbiology and Immunology,¹ Department of Infectious Diseases,²
and Institute of Internal Medicine, Department of Gastroenterology,³
Sahlgrenska University Hospital, Göteborg, Sweden*

Received 20 June 2000/Returned for modification 22 August 2000/Accepted 22 February 2001

The induction of immune responses to rectally administered recombinant cholera toxin B subunit (CTB) in humans was studied. Three immunizations induced high levels of CTB-specific antibody-secreting cells, particular of the immunoglobulin A isotype, in both rectum and peripheral blood. Antitoxin antibody responses in rectal secretions and serum were also found.

Sexually transmitted diseases (STDs) are a major health problem in both industrialized and developing countries. Induction of a local mucosal immune response including the development of specific secretory immunoglobulin A (IgA) antibodies is important for protection against microorganisms that invade via mucosal surfaces (9, 19). One of the portals of entry for sexually transmitted pathogens such as the human immunodeficiency virus and herpes simplex virus is the mucus surface of the rectum. To provide specific protection against such pathogens, it is of great interest to develop immunization schemes that can induce specific immune responses including a strong IgA antibody response in the rectum (6, 10).

The aim of the present study was to assess the rectal immunization route for its ability to induce specific antibody-secreting cell (ASC) responses in suspensions of mononuclear cells (MNCs) from rectal tissues as well as from peripheral blood of healthy volunteers after rectal administration of cholera vaccine containing cholera toxin B subunit (CTB). CTB-specific antibodies in rectal secretions were also collected and analyzed along with antitoxin antibodies in serum.

Subjects and immunization. The study was performed with due informed consent and ethical committee approval on eight healthy volunteers (three women), aged 20 to 44 years, who received three rectal immunizations with an inactivated B subunit-whole cell cholera vaccine, which is normally administered orally. The immunizations were given 2 weeks apart. The vaccine, containing 1.0 mg of recombinantly produced CTB and 10^{11} heat- and formalin-killed vibrios per 3-ml dose (SBL Vaccin, Stockholm, Sweden) (12), was administered by means of a rubber tube, 3 mm in diameter, inserted approximately 5 cm beyond the anus. After administration of the vaccine, the volunteers remained in horizontal position for 30 min.

Collection of specimens. Rectal biopsies (eight persons), rectal secretions (five persons), and blood specimens (eight persons) were collected before the first immunization (day 0) and 7 days after the third vaccine dose. The rectal biopsies were obtained using a rigid sigmoidoscope and a standard flexible endoscope biopsy forceps (Olympus, Solna, Sweden). On each occasion, four to eight pinched biopsy samples 2 mm in diameter, were collected from rectum approximately 8 to 10 cm from the anus. Rectal secretions were collected before pinch biopsies. After insertion of the sigmoidoscope, each of four polywick tampons (2 by 25 mm; Polyfiltronics Inc., Rockland, Mass.), composed of a mixture of synthetic fibers and cellulose, was grasped with the forceps and carefully placed onto a relatively clean mucosal surface in the rectum approximately 12 to 15 cm from the anus. After 5 min, the tampons were collected with the forceps, and each tampon was placed in an Eppendorf tube. To extract proteins from the tampon, 200 μ l of a buffer solution, containing enzyme inhibitors supplemented in 0.1% bovine serum albumin at concentrations previously specified (13), was added. Thereafter, the tubes were centrifuged at $10,000 \times g$ for 2 min at 4°C in order to drive the fluid from the tampon. Supernatants were collected, pooled, and stored at –20°C until analyzed. For determination of circulating vaccine-specific ASC responses, 20 ml of heparinized venous blood was collected from all volunteers immediately before the first immunization and then 7 days after the last immunization. Serum specimens were obtained on the same occasions.

Detection of total and specific Ig-secreting cells. Intestinal MNCs were isolated from the rectal biopsies using an enzymatic dispersion technique as previously described (20). A pool of four to eight biopsy samples from each individual yielded a mean of 2.7×10^5 viable MNCs (range, 0.9×10^5 to 5.9×10^5). MNCs from heparinized venous blood were isolated by standard gradient centrifugation on Ficoll-Isopaque (Pharmacia, Uppsala, Sweden). Rectal and peripheral blood MNC suspensions were assayed for numbers of total IgA- and IgG-secreting cells and CTB-specific IgA and IgG ASCs by a two-color micromodification (4) of the original enzyme-linked

* Corresponding author. Mailing address: Department of Medical Microbiology and Immunology, Göteborg University, Guldhedsgatan 10, 413 46 Göteborg, Sweden. Phone: 46-31-3424614. Fax: 46-31-826976. E-mail: marianne.jertborn@microbio.gu.se.

† Present address: INSERM Unit 364, Faculté de Médecine-Pasteur, Nice, France.

TABLE 1. CTB-specific ASCs and total Ig-secreting cells in rectal biopsy samples from healthy volunteers before and 7 days after three rectal immunizations with recombinant CTB^a

Volunteer	No. of CTB-specific ASCs and total Ig-secreting cells/10 ⁵ MNCs in the rectum							
	IgA				IgG			
	CTB specific		Total Ig		CTB specific		Total Ig	
	Pre	Post	Pre	Post	Pre	Post	Pre	Post
1	<2.5	30	11,000	12,800	<2.5	15	4,000	4,800
2	<2.5	32.5	18,000	20,000	<2.5	<2.5	120	40
3	<2.5	10	16,000	9,000	<2.5	20	1,000	1,000
4	<2.5	22.5	5,600	5,000	<2.5	<2.5	1,000	800
5	<2.5	50	9,000	8,000	<2.5	<2.5	200	100
6	<2.5	250	5,000	4,000	5	25	1,500	1,000
7	<2.5	37.5	10,000	12,000	<2.5	25	3,000	5,000
8	<2.5	25	12,000	15,000	<2.5	5	3,500	4,000

^a Pre and post, pre- and postimmunization.

immunospot method (3, 22). Total Ig and CTB-specific Ig ASCs were expressed per 10⁵ MNCs in the rectum and per 10⁶ MNCs in peripheral blood. Vaccinees who had ≥ 5 CTB-specific ASCs per 10⁵ MNCs in their rectal biopsy samples after vaccination were considered responders when no ASCs, i.e., <2.5 CTB-specific ASCs per 10⁵ MNCs, could be detected prior to immunization. When the preimmune specimens (one case) contained >2.5 CTB-specific ASCs per 10⁵ MNCs, a more than twofold increase in CTB-specific ASCs between pre- and postvaccination samples was considered a vaccine response. The corresponding figure for a response in peripheral blood was set at a postvaccination value of ≥ 5 CTB-specific Ig ASCs per 10⁶ MNCs (5).

Antibody determinations. The content of total IgA1 in rectal secretions was determined with an enzyme-linked immunosorbent assay (ELISA) method as previously described (24). Specific IgA (IgA1) antibody responses to cholera toxin in rectal secretions were measured by a GM1 ELISA method (23). The antibody titer was determined as the interpolated dilution of the specimen giving an absorbance value at 405 nm of 0.4 above background. The specific IgA antitoxin activities in rectal secretions were determined by dividing the IgA ELISA antibody titer by the total IgA concentration (micrograms per milliliter) of the sample to adjust for variations in the IgA content in specimens collected from different persons and on various days. A greater than twofold increase in the mean IgA antibody titer/total IgA between pre- and postimmunization specimens was regarded as a response (1). When preimmune specimens were missing (two cases), volunteers were considered responders if their postvaccination IgA antitoxin titer/total IgA exceeded by 2 standard deviations the geometric mean IgA antitoxin titer/total IgA in rectal secretions from seven other nonimmunized individuals.

Serum antibody responses of IgA and IgG classes to cholera toxin were measured by the GM1 ELISA method (23). A twofold or greater increase in endpoint titer between pre- and postvaccination specimens was used to signify seroconversion at a *P* value of <0.05 (11, 12).

Local immune responses in the rectum. The frequencies of total IgA and IgG secreting cells were similar in rectal biopsy samples obtained before and after three rectal administrations of CTB (Table 1). Prior to immunization, no CTB-specific IgA

or IgG ASCs were found in the rectum, except for one individual who had 5 IgG ASCs per 10⁵ MNCs. The vaccination induced substantial increases in CTB-specific IgA ASCs in the rectum in each of the eight volunteers, with a geometric mean fold increase in ASCs of more than 14-fold (Table 1; Fig. 1a). Increases in CTB-specific IgG ASCs were also seen in five (63%) of the volunteers after vaccination, and the geometric mean fold rise in ASCs for these responders was more than fivefold (Table 1; Fig. 1a).

The local immune response in the rectum was also measured as CTB-specific IgA (IgA1) antibodies in secretions from the rectal surface collected by using a tampon method (16). This method was shown to give a yield of IgA antibodies high enough to allow detection of vaccine-specific IgA antibodies in sample eluates. A total of eight secretions collected from five




FIG. 1. Levels of CTB-specific IgA and IgG ASCs in the rectum (a) and peripheral blood (b) of healthy volunteers 7 days after three rectal administrations of recombinant CTB. The geometric mean numbers of vaccine-specific ASCs + 1 standard error of the mean are shown.




FIG. 2. Intestinal IgA (IgA1) antitoxin levels in rectal secretions collected from five volunteers before (Pre) and 7 days after (Post) three rectal administrations of recombinant CTB. The dotted line denotes the geometric mean IgA antitoxin titer/total IgA in rectal secretions from seven nonimmunized individuals. Preimmune specimens were missing for two vaccinees.

volunteers (preimmune specimens were missing in two cases) contained as a mean $200 \mu\text{g}$ of total IgA ml^{-1} (range, 18 to $501 \mu\text{g} \text{ml}^{-1}$). All of the five volunteers responded to the rectal immunization with increases in CTB-specific IgA antibody titer/total IgA in rectal secretions (Fig. 2).

Immune responses in blood. Monitoring of different homing receptors on circulating ASCs indicates that especially ASCs of the IgA isotype, assayed approximately 7 days after oral or rectal vaccination, almost exclusively represent cells of the intestinal immune system (15). Prior to immunization, the number of circulating CTB-specific IgA and IgG ASCs were negligible ($\leq 1 \text{ ASC} \times 10^6 \text{ MNCs}$). All of the eight volunteers responded with increased numbers of CTB-specific IgA ASCs in blood after three rectal administrations of CTB (Table 2), with a geometric mean fold increase of more than 19-fold (Fig. 1b). Increased levels of circulating IgG ASCs against CTB were also found in four (50%) of the volunteers after vaccina-

tion (Table 2; Fig. 2), and the mean fold increase in ASCs for these responders was more than 27-fold. There were also significant increases in serum IgA antitoxin titers in six (75%) of eight volunteers after three rectal doses of CTB, and seven (88%) of the vaccinees developed IgG antitoxin responses too (Table 2). Among responders, these increases in antitoxin were 7.6-fold for IgA and 4.4-fold for IgG.

The individual ASC responses to CTB in peripheral blood were compared with corresponding ASC responses in the rectum. A significant correlation between the magnitudes of CTB-specific ASCs in the rectum and in blood was found for IgG ($r = 0.71$; $P < 0.01$), whereas no such correlation was observed for IgA ASCs.

In conclusion, the results presented show that the human rectal mucosa can serve as an efficient site for both the induction and expression of local mucosal IgA and IgG antibody responses. The substantial increases in specific IgA antibodies in rectal secretions were consistent with results obtained after repeated rectal immunizations with inactivated cholera vaccine (16) or live *Salmonella enterica* serovar Typhi Ty21a vaccine (15). The magnitudes of the CTB-specific IgA and IgG responses, in terms of both specific ASCs in rectal biopsies and antibodies in rectal secretions, were similar to those to CTB in the small intestine reported after oral cholera vaccination (13, 18, 21). The appearance of specific IgA and IgG ASCs in blood after rectal immunization with CTB was also in accordance with results obtained in humans after oral or rectal immunization with *S. enterica* serovar Typhi Ty21a vaccine (8, 15).

CTB was chosen as the immunogen in our studies for several reasons: (i) CTB is a well-defined potent mucosal immunogen, which has been used in several previous studies of mucosal immune responses, especially within the gastrointestinal tract (13, 16, 18, 21); (ii) CTB can be safely administered to humans in the form of a registered oral cholera vaccine (12, 13); and (iii) CTB has in animals been shown to serve as an effective carrier molecule for enhancing the mucosal immunogenicity of various antigens linked chemically or genetically to CTB (2, 7, 14, 17). The latter finding together with the present results suggests that rectal immunization with CTB, and probably also with other antigens linked to CTB, could work well to elicit local mucosal IgA and IgG immune responses and thus allow for effective mucosal immunization of the rectal portal of entry

TABLE 2. CTB-specific ASCs and total Ig-secreting cells in peripheral blood and antitoxin antibodies in serum in healthy volunteers before and 7 days after three rectal immunizations with recombinant CTB^a

Volunteer	No. of CTB-specific ASCs and total Ig-secreting cells/ 10^6 MNCs in blood								Antitoxin antibodies in serum			
	IgA				IgG				IgA		IgG	
	CTB-specific		Total Ig		CTB-specific		Total Ig					
	Pre	Post	Pre	Post	Pre	Post	Pre	Post	Pre	Post	Pre	Post
1	<1	23	220	400	<1	15	300	400	5	69	14	195
2	<1	30	350	500	<1	<1	280	350	5	11	58	148
3	<1	15	180	350	<1	50	400	700	3	135	40	339
4	<1	14	500	700	<1	4	500	500	4	32	47	112
5	1	20	750	480	<1	2	150	200	35	93	52	112
6	<1	10	300	180	1	4	280	360	7	56	49	347
7	<1	40	200	260	<1	28	650	800	22	33	68	91
8	<1	18	150	200	<1	24	480	730	589	603	85	269

^a Pre and post, pre- and postimmunization.

for specific STD pathogens. These findings should be relevant for the development of vaccines against human immunodeficiency virus infection as well as other STDs.

REFERENCES

1. Åhrén, C., C. Wennerås, J. Holmgren, and A.-M. Svennerholm. 1993. Intestinal antibody response after oral immunization with a prototype cholera B subunit-colonization factor antigen enterotoxigenic *Escherichia coli* vaccine. *Vaccine* 11:929-934.
2. Bergquist, C., T. Lagergård, M. Lindblad, and J. Holmgren. 1995. Local and systemic antibody responses to dextran-cholera toxin B subunit conjugates. *Infect. Immun.* 63:2021-2025.
3. Czerkinsky, C., L.-Å. Nilsson, H. Nygren, Ö. Ouchterlony, and A. A. Tarkowski. 1983. Solid-phase enzyme-linked immunospot (ELISPOT) assay for enumeration of specific antibody-secreting cells. *J. Immunol. Methods* 65:109-121.
4. Czerkinsky, C., Z. Moldoveanu, J. Mestecky, L.-Å. Nilsson, and Ö. Ouchterlony. 1988. A novel two colour ELISPOT assay. Simultaneous detection of distinct types of antibody-secreting cells. *J. Immunol. Methods* 115:31-37.
5. Czerkinsky, C., A.-M. Svennerholm, M. Quiding, R. Jonsson, and J. Holmgren. 1991. Antibody-producing cells in peripheral blood and salivary glands after oral cholera vaccination of humans. *Infect. Immun.* 59:996-1001.
6. Czerkinsky, C., F. Anjuere, J. R. McGhee, A. George-Chandy, J. Holmgren, M. P. Kieny, K. Fujiyoshi, J. F. Mestecky, V. Pierrefite-Carle, C. Rask, and J. B. Sun. 1999. Mucosal immunity and tolerance: relevance to vaccine development. *Immunol. Rev.* 170:197-222.
7. Drew, M. D., A. Estrada-Correa, B. J. Underdown, and M. R. McDermott. 1992. Vaccination by cholera toxin conjugated to a herpes simplex virus type 2 glycoprotein D peptide. *J. Gen. Virol.* 73:2357-2366.
8. Forrest, B. D., D. J. C. Shearman, and J. T. LaBrooy. 1990. Specific immune response in humans following rectal delivery of live typhoid vaccine. *Vaccine* 8:209-212.
9. Holmgren, J., and A. Rudin. 1999. Mucosal immunity and bacteria, p. 685-693. *In* P. L. Ogra, J. Mestecky, M. E. Lamm, W. Strober, J. Bienenstock, and J. R. McGhee (ed.), *Mucosal immunology*, 2nd ed. Academic Press, San Diego, Calif.
10. Hook, III, E. W., M. S. Pate, S. R. Hedges, M. W. Russell, and J. Mestecky. 1999. Mucosal immunology of sexually transmitted diseases, p. 1463-1481. *In* P. L. Ogra, J. Mestecky, M. E. Lamm, W. Strober, J. Bienenstock, and J. R. McGhee (ed.), *Mucosal immunology*, 2nd ed. Academic Press, San Diego, Calif.
11. Jertborn, M., A.-M. Svennerholm, and J. Holmgren. 1986. Saliva, breast milk, and serum antibody responses as indirect measures of intestinal immunity after oral cholera vaccination or natural disease. *J. Clin. Microbiol.* 24:203-209.
12. Jertborn, M., A.-M. Svennerholm, and J. Holmgren. 1992. Safety and immunogenicity of an oral recombinant cholera B subunit-whole cell vaccine in Swedish volunteers. *Vaccine* 2:130-132.
13. Jertborn, M., A.-M. Svennerholm, and J. Holmgren. 1996. Intestinal and systemic immune responses in humans after oral immunization with a bivalent B subunit-01/0139 whole cell cholera vaccine. *Vaccine* 14:1459-1465.
14. Johansson, E.-L., C. Rask, M. Fredriksson, K. Eriksson, C. Czerkinsky, and J. Holmgren. 1998. Antibodies and antibody-secreting cells in the female genital tract after vaginal or intranasal immunization with cholera toxin B subunit or conjugates. *Infect. Immun.* 66:514-520.
15. Kantele, A., M. Häkkinen, Z. Moldoveanu, A. Lu, E. Savilahti, R. D. Alvarez, S. Michalek, and J. Mestecky. 1998. Differences in immune responses induced by oral and rectal immunizations with *Salmonella typhi* Ty21a: evidence for compartmentalization within the common mucosal immune system in humans. *Infect. Immun.* 66:5630-5635.
16. Kozłowski, P. A., S. Cu-Uvin, M. R. Neutra, and T. P. Flanagan. 1997. Comparison of the oral, rectal, and vaginal immunization routes for induction of antibodies in rectal and genital tract secretions of women. *Infect. Immun.* 65:1387-1394.
17. Lehner, T., L. A. Bergmeier, C. Panagiotidi, L. Tao, R. Brookes, L. S. Klavinskis, P. Walker, J. Ward, R. D. Ward, L. Hussain, et al. 1992. Induction of mucosal and systemic immunity to a recombinant simian immunodeficiency viral protein. *Science* 258:1365-1369.
18. Mattsson, A., H. Lönnroth, M. Quiding-Järbrink, and A.-M. Svennerholm. 1998. Induction of B-cell responses in the stomach of *Helicobacter pylori*-infected subjects after oral cholera vaccination. *J. Clin. Investig.* 102:51-56.
19. Murphy, B. R. 1999. Mucosal immunity to viruses, p. 695-707. *In* P. L. Ogra, J. Mestecky, M. E. Lamm, W. Strober, J. Bienenstock, and J. R. McGhee (ed.), *Mucosal immunology*, 2nd ed. Academic Press, San Diego, Calif.
20. Nordström, I., M. Quiding, B. Kjellson, A. Kilander, E. Ahlfors, J. Holmgren, and C. Czerkinsky. 1990. Thermolysin treatment: an improved dispersion technique for isolating functional lymphoid cells from human intestinal tissues, p. 103-104. *In* T. T. McDonalds, S. J. Challacombe, P. W. Bland, C. R. Stokes, R. V. Heatley, and A. M. Mowat (ed.), *Advances in mucosal immunology*. Kluwer Academic Publishers, Dordrecht, The Netherlands.
21. Quiding, M., I. Nordström, A. Kilander, G. Andersson, L. Å. Hanson, J. Holmgren, and C. Czerkinsky. 1991. Oral cholera vaccination induces strong intestinal antibody responses and interferon- γ production and evokes local immunological memory. *J. Clin. Investig.* 88:143-148.
22. Sedgwick, J. D., and P. G. Holt. 1983. A solid-phase immunoenzymatic technique for the enumeration of specific antibody-secreting cells. *J. Immunol. Methods* 57:301-309.
23. Svennerholm, A.-M., J. Holmgren, R. Black, M. Levine, and M. Merson. 1983. Serologic differentiation between antitoxin responses to infection with *Vibrio cholerae* and enterotoxin-producing *Escherichia coli*. *J. Infect. Dis.* 147:514-522.
24. Vincent, C., G. Cozon, M. Zittoun, M. Mellquist, M. D. Kazatchkine, C. Czerkinsky, and J.-P. Revillard. 1992. Secretory immunoglobulins in serum from human immunodeficiency virus (HIV)-infected patients. *J. Clin. Immunol.* 12:381-388.